Get the Stockscreener App
80.50
7.35%
5.51
After Hours:
80.30
-0.20
-0.25%
Veradermics Inc stock is traded at $80.50, with a volume of 545.15K.
It is up +7.35% in the last 24 hours and up +52.46% over the past month.
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
See More
Previous Close:
$74.99
Open:
$75.03
24h Volume:
545.15K
Relative Volume:
1.59
Market Cap:
$3.01B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-85.64
EPS:
-0.94
Net Cash Flow:
-
1W Performance:
+38.70%
1M Performance:
+52.46%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$73.36
$80.50
1-Week Range:
$57.20
$80.50
52-Week Range:
$32.00
$80.50
Veradermics Inc Stock (MANE) Company Profile
Name
Veradermics Inc
Sector
Industry
Phone
228.372.3376
Address
470 JAMES STREET, NEW HAVEN
Compare MANE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MANE
Veradermics Inc
|
80.50 | 2.80B | 0 | 0 | 0 | -0.94 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Veradermics Inc Stock (MANE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-02-26 | Initiated | Citigroup | Buy |
| Mar-02-26 | Initiated | Jefferies | Buy |
| Mar-02-26 | Initiated | Leerink Partners | Outperform |
Veradermics Inc Stock (MANE) Latest News
MANE Stock Price and Chart — NYSE:MANE - TradingView — Track All Markets
Veradermics (MANE) Reports Q4 Net Loss of $21.8M - Yahoo Finance
ETFs Investing in Veradermics, Incorporated Stocks - TradingView — Track All Markets
Number of employees of Veradermics, Incorporated – NYSE:MANE - TradingView — Track All Markets
MANE Forecast — Price Target — Prediction for 2027 - TradingView — Track All Markets
Veradermics, Incorporated Statistics – BX:MANE - TradingView — Track All Markets
Biopharma IPOs Had Their Best Showing In More Than A Year In Q1 - Citeline News & Insights
AMD, Avago among market cap stock movers on Friday - Investing.com
AMD, Avago among market cap stock movers on Friday By Investing.com - Investing.com India
Veradermics, Incorporated: Fundamental Analysis and Financial Ratings | MANE | US9229671048 - marketscreener.com
VeraDermics Surges 9%—Yet Major Investors Remain Cautious - Bitget
MANE SEC FilingsVERADERMICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
MANE: Veradermics IncorporatedBrokerage Recommendations Chart - Zacks Investment Research
Veradermics Shares More Than Double in NYSE Debut - MarketScreener
Citi Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $85 - Moomoo
VeraDermics (MANE) Plummets 7% as Intraday Volatility Unfolds — What's Fueling the Sharp Drop? - Bitget
Veradermics (NYSE: MANE) bets on oral minoxidil for pattern hair loss - Stock Titan
Veradermics, Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Veradermics Reports Strong 2025 Financials, Completes Key VDPHL01 Trials, and Raises $295M IPO to Fund Operations Into 2029 - Minichart
Veradermics (NYSE: MANE) deepens 2025 loss after $294.8M IPO cash boost - Stock Titan
MANE: Raised $294.8M in IPO, completed key trial enrollment, and reported a $70M net loss for 2025 - TradingView
Earnings Flash (MANE) Veradermics Posts Q4 Net Loss $21.8M - marketscreener.com
Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates - businesswire.com
Jefferies reiterates Buy on Veradermics stock, $75 target By Investing.com - Investing.com Canada
Veradermics, Incorporated(NYSE: MANE) added to S&P TMI Index - marketscreener.com
Veradermics to present hair loss treatment data at AAD meeting By Investing.com - Investing.com South Africa
Veradermics Announces Presentations on VDPHL01 and Patient Experi - The National Law Review
Veradermics to present hair loss treatment data at AAD meeting - Investing.com
Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting - Business Wire
Veradermics Inc (MANE) Financial Ratios - Investing.com India
Veradermics (MANE) Stock Analysis Report | Financials & Insights - Benzinga Japan
Is Veradermics (MANE) Pricing Look Attractive After Recent Pharma Sector Reappraisal? - Yahoo Finance
MANE Should I Buy - Intellectia AI
A Look At Veradermics (MANE) Valuation After Recent Share Price Momentum And DCF Upside Signals - simplywall.st
Dermatology drug maker Veradermics set for Miami investor spotlight - Stock Titan
Veradermics to Participate in Upcoming March Investor Conferences - ChartMill
Veradermics, Incorporated: Revenue and Earnings Analysts Forecasts Revisions | MANE | US9229671048 - marketscreener.com
MANE Technical Analysis & ETF Price Forecast - Intellectia AI
Veradermics, Incorporated: Dividend historical data and projections - marketscreener.com
Leerink initiates Veradermics stock with Outperform rating By Investing.com - Investing.com UK
Cantor Fitzgerald Initiates VeraDermics at Overweight - marketscreener.com
Jefferies Initiates VeraDermics at Buy With $75 Price Target - marketscreener.com
Citigroup Initiates VeraDermics at Buy With $85 Price Target - marketscreener.com
Leerink Initiates VeraDermics at Outperform With $75 Price Target - marketscreener.com
Veradermics eyes FDA first as Jefferies initiates at 'buy'; sees 75% upside on oral hair loss pill - Proactive financial news
Leerink initiates Veradermics stock with Outperform rating - Investing.com South Africa
Jefferies initiates Veradermics stock with buy rating on phase 3 prospects - Investing.com Canada
Cantor Fitzgerald initiates Veradermics stock with Overweight rating By Investing.com - Investing.com Canada
Cantor Fitzgerald initiates Veradermics stock with Overweight rating - Investing.com
Flagship-Backed Generate Biomedicines Raises $400 Million in IPO - Bloomberg.com
Flagship-Backed Generate Bio Seeks $425 Million in US IPO - Bloomberg.com
Veradermics Inc Stock (MANE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):